JP2021501566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501566A5 JP2021501566A5 JP2020518692A JP2020518692A JP2021501566A5 JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5 JP 2020518692 A JP2020518692 A JP 2020518692A JP 2020518692 A JP2020518692 A JP 2020518692A JP 2021501566 A5 JP2021501566 A5 JP 2021501566A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- amino acid
- antibody
- acid sequence
- transmembrane domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 120
- 210000004027 cell Anatomy 0.000 claims description 62
- 150000001413 amino acids Chemical class 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 47
- 125000000539 amino acid group Chemical group 0.000 claims description 41
- 239000012528 membrane Substances 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 22
- 210000001723 extracellular space Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 15
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 10
- 108010087819 Fc receptors Proteins 0.000 claims description 8
- 102000009109 Fc receptors Human genes 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 102000006495 integrins Human genes 0.000 claims description 6
- 108010044426 integrins Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000004897 n-terminal region Anatomy 0.000 claims description 5
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 4
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 4
- 108010021470 Fc gamma receptor IIC Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 4
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 claims description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000003979 eosinophil Anatomy 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 201000009295 smoldering myeloma Diseases 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186940A JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566936P | 2017-10-02 | 2017-10-02 | |
| US62/566,936 | 2017-10-02 | ||
| US201862725880P | 2018-08-31 | 2018-08-31 | |
| US62/725,880 | 2018-08-31 | ||
| PCT/US2018/053989 WO2019070726A1 (en) | 2017-10-02 | 2018-10-02 | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186940A Division JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501566A JP2021501566A (ja) | 2021-01-21 |
| JP2021501566A5 true JP2021501566A5 (OSRAM) | 2021-11-11 |
Family
ID=63966111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518692A Pending JP2021501566A (ja) | 2017-10-02 | 2018-10-02 | Ｃｄ１３８に対する抗体分子およびその使用 |
| JP2023186940A Pending JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186940A Pending JP2024001294A (ja) | 2017-10-02 | 2023-10-31 | Ｃｄ１３８に対する抗体分子およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11945868B2 (OSRAM) |
| EP (1) | EP3692069A1 (OSRAM) |
| JP (2) | JP2021501566A (OSRAM) |
| KR (1) | KR20200058540A (OSRAM) |
| CN (2) | CN111183157A (OSRAM) |
| AU (1) | AU2018345637A1 (OSRAM) |
| BR (1) | BR112020005419A2 (OSRAM) |
| CA (1) | CA3074032A1 (OSRAM) |
| IL (2) | IL273572B2 (OSRAM) |
| MX (1) | MX2020003783A (OSRAM) |
| MY (1) | MY205689A (OSRAM) |
| PH (1) | PH12020550141A1 (OSRAM) |
| SG (1) | SG11202002248TA (OSRAM) |
| WO (1) | WO2019070726A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7254029B2 (ja) * | 2017-04-26 | 2023-04-07 | 田辺三菱製薬株式会社 | Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用 |
| CA3074032A1 (en) | 2017-10-02 | 2019-04-11 | Visterra, Inc. | Antibody molecules to cd138 and uses thereof |
| MX2021016098A (es) | 2019-06-17 | 2022-02-03 | Visterra Inc | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. |
| KR20220051177A (ko) | 2019-07-26 | 2022-04-26 | 비스테라, 인크. | 인터류킨-2 작용제 및 이의 용도 |
| US20220390455A1 (en) * | 2019-11-05 | 2022-12-08 | Bristol-Myers Squibb Company | M-protein assays and uses thereof |
| KR20230129018A (ko) | 2020-12-04 | 2023-09-05 | 비스테라, 인크. | 인터류킨-2 작용제를 사용하는 방법 |
| US20240319194A1 (en) * | 2021-06-29 | 2024-09-26 | Sheba Impact Ltd. | Diagnosis and treatment of pancreatic cancer |
| CN113514645A (zh) * | 2021-07-13 | 2021-10-19 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | CD138抗体联合Mum1抗体在检测浆细胞中的应用 |
| US20230348614A1 (en) | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| CN115120725B (zh) * | 2022-05-30 | 2023-11-07 | 南方医科大学 | Sdc1作为骨质破坏疾病药物治疗靶点的应用 |
| CN115960231A (zh) * | 2022-09-28 | 2023-04-14 | 合肥天港免疫药物有限公司 | 抗cd138的抗体及其应用 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| JP4392163B2 (ja) | 2000-06-21 | 2009-12-24 | 日立化成工業株式会社 | 肺癌用遺伝子マーカー |
| AU2004224925C1 (en) | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| EA037929B1 (ru) | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
| US20070054332A1 (en) * | 2005-08-10 | 2007-03-08 | Alan Rapraeger | Syndecan 1 ectodomain inhibits cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| KR101579218B1 (ko) | 2007-12-26 | 2015-12-21 | 바이오테스트 아게 | Ｃｄ138 발현성 종양 세포에 대한 표적화를 개선시키기 위한 방법 및 물질 |
| HRP20150143T1 (hr) | 2007-12-26 | 2015-04-10 | Biotest Ag | Imunokonjugati koji ciljaju na cd138 i njihova upotreba |
| CN101952315B (zh) | 2007-12-26 | 2015-04-01 | 生物测试股份公司 | 靶向cd138的试剂及其应用 |
| EP2238169A1 (en) | 2007-12-26 | 2010-10-13 | Biotest AG | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| JP2012526079A (ja) | 2009-05-06 | 2012-10-25 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体の使用 |
| US9249467B2 (en) | 2011-09-16 | 2016-02-02 | Steven Goodison | Bladder cancer detection composition, kit and associated methods |
| US10577543B2 (en) | 2011-10-27 | 2020-03-03 | Raymond Roger Wallage | Efficient oil shale recovery method |
| AU2012372140B9 (en) | 2011-12-08 | 2015-10-15 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| NZ630020A (en) | 2012-03-08 | 2016-08-26 | Halozyme Inc | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| GB201216002D0 (en) | 2012-09-07 | 2012-10-24 | Deutsches Rheuma Forschungszentrum Berlin Drfz | Compositions adn methods |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| CN103103197A (zh) | 2013-01-30 | 2013-05-15 | 百奇生物科技（苏州）有限公司 | 抗cd138单克隆抗体可变区序列及其制备方法和应用 |
| RU2611685C2 (ru) | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| CA3074032A1 (en) | 2017-10-02 | 2019-04-11 | Visterra, Inc. | Antibody molecules to cd138 and uses thereof |
| US12172986B2 (en) | 2018-06-01 | 2024-12-24 | Eisai R&D Management Co., Ltd | Splicing modulator antibody-drug conjugates and methods of use |
| CN114144437B (zh) | 2019-06-07 | 2025-02-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| MX2021016098A (es) | 2019-06-17 | 2022-02-03 | Visterra Inc | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. |
| US20220281997A1 (en) | 2019-09-27 | 2022-09-08 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH Domain Antibodies and Use Thereof |
| US20230348614A1 (en) | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
-
2018
- 2018-10-02 CA CA3074032A patent/CA3074032A1/en active Pending
- 2018-10-02 EP EP18793101.9A patent/EP3692069A1/en active Pending
- 2018-10-02 MX MX2020003783A patent/MX2020003783A/es unknown
- 2018-10-02 IL IL273572A patent/IL273572B2/en unknown
- 2018-10-02 KR KR1020207012740A patent/KR20200058540A/ko not_active Ceased
- 2018-10-02 AU AU2018345637A patent/AU2018345637A1/en not_active Abandoned
- 2018-10-02 CN CN201880064634.XA patent/CN111183157A/zh active Pending
- 2018-10-02 BR BR112020005419-4A patent/BR112020005419A2/pt not_active Application Discontinuation
- 2018-10-02 CN CN202411128002.9A patent/CN119192374A/zh active Pending
- 2018-10-02 SG SG11202002248TA patent/SG11202002248TA/en unknown
- 2018-10-02 IL IL320863A patent/IL320863A/en unknown
- 2018-10-02 WO PCT/US2018/053989 patent/WO2019070726A1/en not_active Ceased
- 2018-10-02 JP JP2020518692A patent/JP2021501566A/ja active Pending
- 2018-10-02 US US16/149,854 patent/US11945868B2/en active Active
- 2018-10-02 MY MYPI2020001188A patent/MY205689A/en unknown
-
2020
- 2020-03-26 PH PH12020550141A patent/PH12020550141A1/en unknown
-
2023
- 2023-10-31 JP JP2023186940A patent/JP2024001294A/ja active Pending
-
2024
- 2024-02-20 US US18/581,992 patent/US20240301065A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501566A5 (OSRAM) | ||
| JP7179464B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| AU2010292342C1 (en) | High affinity human antibodies to human protease-activated receptor-2 | |
| JP2020115876A (ja) | Ｐｄ−ｌ１に対するヒト抗体 | |
| US11945868B2 (en) | Antibody molecules to CD138 and uses thereof | |
| JP2023516936A (ja) | Ｐｖｒｉｇ結合タンパク質及びその医薬用途 | |
| CN106068275A (zh) | 抗pd‑1的人抗体 | |
| TW201006493A (en) | Compositions and methods of use for therapeutic antibodies | |
| WO2020198370A2 (en) | Therapeutic cd47 antibodies | |
| KR20230058074A (ko) | Ilt2에 대한 항체 및 이의 용도 | |
| JP2025041695A (ja) | 抗体および使用方法 | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| JP2024097985A (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| CA3207703A1 (en) | Anti-s100a4 humanized antibodies, uses and methods | |
| AU2018361819A1 (en) | Antibodies and methods of use | |
| US20250051473A1 (en) | Anti-cd38 binding molecules and uses thereof | |
| WO2020132654A1 (en) | Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof | |
| KR20230087552A (ko) | Cd45를 다량체화하는 결합 분자 | |
| CN114641500A (zh) | 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法 | |
| CN118679185A (zh) | 抗cd38结合分子及其用途 | |
| CA3250219A1 (en) | ANTIBODIES AGAINST BTLA AND THEIR USES | |
| HK40074321A (en) | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies | |
| EA050239B1 (ru) | Мультиспецифические антитела, связывающиеся с bcma | |
| EA048356B1 (ru) | МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28 |